Commercial clients of Navitus Health Solutions saw a 60% reduction in net cost per claim after the PBM removed the arthritis drug Humira (adalimumab) from its formularies in favor of three biosimilar options. Navitus is forecasting annualized net savings of more than $100 million with the transition to adalimumab biosimilars that have a low wholesale acquisition cost and low rebates, according to the company’s most recent Drug Trend Report.

Navitus removed Humira from its formularies in June 2024, preferring instead adalimumab-adaz (an equivalent of the biosimilar Hyrimoz), adalimumab-fkjp (an equivalent of the biosimilar Hulio), and Hadlima. Within three months of the formulary change, 94% of members successfully switched to a biosimilar, according to an analysis done by Navitus rese

See Full Page